ClinicalTrials.gg
Active, not recruitingNCT00840047Updated Jun 17, 2026

Methionine PET/CT Studies In Patients With Cancer

A Phase 2 interventional study of Methionine in Brain Tumors and/or Solid Tumors Including, Brain Stem Glioma and High Grade CNS Tumors, sponsored by St. Jude Children's Research Hospital. Active, not recruiting at 1 site in United States. Per ClinicalTrials.gov, last updated 2026-06-17.

Sponsored by St. Jude Children's Research Hospital · Phase 2, Interventional, and Diagnostic

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
503
Allocation
Not applicable
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 182 studies in Ependymoma with a site in United States — 16 open to participants now, 42 under way, none of them phase 3. Ependymoma · United States.

Enrollment
2nd of 155
503 · median 24
Started
2009
with 6 others
Phase 2
60 of 182
3 open now
Primary completion
2027-07
later than 22 of 40 live
Registered
59th of 182
by date
Lead sponsor
6 of 182
St. Jude Children's Research Hospital

Among the 182 studies in Ependymoma with a site in United States, this one is the 2nd largest by enrollment of the 155 interventional ones that give a count, is one of 7 that started in 2009, is one of 60 in phase 2, reaches primary completion later than 22 of the 40 other live ones, and was the 59th registered.

Ependymoma

224 studies on the registry are indexed under Ependymoma; 35 are open to participants now.

Browse Ependymoma studies →

Open to participants now

16 of the 182 studies in Ependymoma with a site in United States are open now. Recruiting first, the newest first:

11 more — sign in →

All 16 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 25 Ependymoma studies recruiting now, 7 (28%) set no upper age limit and 16 (64%) stop at 75 or younger; 19 take children under 18; 1 takes healthy volunteers.

This study: all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 182 studies in Ependymoma with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to test the usefulness of imaging with radiolabeled methionine in the evaluation of children and young adults with tumor(s). Methionine is a naturally occurring essential amino acid. It is crucial for the formation of proteins. When labeled with carbon-11 (C-11), a radioactive isotope of the naturally occurring carbon-12, the distribution of methionine can be determined noninvasively using a PET (positron emission tomography) camera. C-11 methionine (MET) has been shown valuable in the monitoring of a large number of neoplasms. Since C-11 has a short half life (20 minutes), MET must be produced in a facility very close to its intended use. Thus, it is not widely available and is produced only at select institutions with access to a cyclotron and PET chemistry facility. With the new availability of short lived tracers produced by its PET chemistry unit, St. Jude Children's Research Hospital (St. Jude) is one of only a few facilities with the capabilities and interests to evaluate the utility of PET scanning in the detection of tumors, evaluation of response to therapy, and distinction of residual tumor from scar tissue in patients who have completed therapy. The investigators propose to examine the biodistribution of MET in patients with malignant solid neoplasms, with emphasis on central nervous system (CNS) tumors and sarcomas. This project introduces a new diagnostic test for the noninvasive evaluation of neoplasms in pediatric oncology. Although not the primary purpose of this proposal, the investigators anticipate that MET studies will provide useful clinical information for the management of patients with malignant neoplasms.

Read the detailed description

The study focuses on the following objectives:

Primary objective:

  • To estimate the success rate of Methionine (MET) for visualizing tumors at the time of diagnosis. The study hypothesizes that at least 70% of newly diagnosed tumors within each group will be studied and will be successfully visualized.

Secondary objective:

  • To compare uptake of MET in tumors with tumor grade in patients with newly diagnosed or relapsed, and/or persistent disease. Hypothesis: high grade tumors will concentrate higher amounts of MET than lower grade tumors measured both qualitatively and semi-quantitatively.
  • To examine the bio-distribution of MET in organs that do not contain tumor, in particular the lungs, heart, mediastinum, liver, spleen, pancreas, muscle, brain, and bone marrow.

Exploratory objectives:

  • To compare the findings on MET PET scans with those of standard imaging modalities, principally MRI (magnetic resonance imaging) and FDG (fluorodeoxyglucose) PET CT (computed tomography) at diagnosis, or at study enrollment for patients with relapsed and or persistent disease, and for all patients over time.
  • To compare the extent of abnormality on MRI with that of MET.
  • To determine the presence or absence of elevated MET uptake beyond those of MRI defined abnormality.
  • To explore the relationship between MET uptake and prognosis.
03

Conditions studied

  • Brain Tumors and/or Solid Tumors Including
  • Brain Stem Glioma
  • High Grade CNS Tumors
  • Ependymoma
  • Medulloblastoma
  • Craniopharyngioma
  • Low Grade CNS Tumors
  • Hodgkin Lymphoma
  • Non Hodgkin Lymphoma
  • Ewing Sarcoma
  • Osteosarcoma
  • Rhabdomyosarcoma
  • Neuroblastoma
  • Other

Keywords

  • Pediatric brain tumor
  • Pediatric solid tumor
  • Pediatric solid neoplasms
04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria:

  • All participants under the care of St. Jude physicians with known or suspected neoplastic disease are eligible for participation.
  • Participants will have had, or are scheduled to have clinical imaging evaluations which may include FDG PET CT, or CT, or MRI within 4 weeks of entry.
  • No limit on age or gender.
  • Female participants of childbearing age must not be lactating due to theoretical potential harm to the infant from exposure to radiation.
  • signed by participant, parent, or guardian according to the guidelines of the institutional review board.

Exclusion Criteria:

  • More than 6 MET PET scans within the previous 12 months.
  • Inability or unwillingness of research participant, parent, or legal guardian/representative to give written informed consent.

Inclusion Criteria for Open-Access

  • All participants under the care of St. Jude physicians with known or suspected neoplastic disease are eligible for participation.
  • No limit on age or gender
  • Female participants of childbearing age must not be lactating due to theoretical potential harm to the infant from exposure to radiation.
  • Informed consent signed by participant, parent, or guardian according to the guidelines of the institutional review board.

Exclusion Criteria for Open-Access

  • More than 6 MET PET scans within the previous 12 months.
  • Inability or unwillingness of research participant, parent, or legal guardian/representative to give written informed consent.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 2
Primary purpose
Diagnostic
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
503 participants (actual)

Study arms

  • Experimental
    Participants

    Participants who meet the eligibility criteria in the study will receive methionine.

    Drug: Methionine

Interventions

  • Intravenous injection

    Also known as: MET, [11C]-L-Methionine

06

What researchers measure

Primary outcomes

  1. Success rate of methionine (MET) for visualizing tumors

    To estimate the success rate of methionine (MET) for visualizing tumors at the time of diagnosis. We hypothesize that at least 70% of tumors within each group studied will be successfully visualized.

    Time frame: Baseline

Secondary outcomes

  1. Association of methionine uptake with tumor grade

    Methionine uptake in tumors will be compared among tumor grades in patients with newly diagnosed or relapsed, and/or persistent disease. Hypothesis: high-grade tumors will concentrate higher amounts of MET than lower-grade tumors measured both qualitatively and semi-quantitatively.

    Time frame: End of study (maximum of 3 years post methionine infusion and PET scan)

  2. Bio-distribution of MET in organs

    Whole body scans will be acquired and descriptive statistics for MET uptake from other parts of the body will be provided.

    Time frame: At baseline, after enrollment of the first 93 participants

07

Study locations

1 site
08

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2009 (actual). Primary completion is estimated for Jul 2027, 216 months after the start.

Of 34 non-industry phase 2 interventional studies under Ependymoma, half reached primary completion within 66 months of starting (the median), counting those still running; a quarter within 47 and three quarters within 108. This study's planned 216 months is above that.

Counting every sponsor, half of 35 studies reached it within 67 months; a quarter within 52 and three quarters within 108.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 9, 2009
First posted
Feb 10, 2009
StartActual
Jul 20, 2009
Primary completionEst.
Jul 27, 2027
CompletionEst.
Jul 27, 2027
Last update
Jun 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 17, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00840047
Responsible party
Sponsor
First posted
Feb 10, 2009
Start date
Jul 20, 2009
Primary completion
Jul 27, 2027 (estimated)
Completion
Jul 27, 2027 (estimated)
Last update
Jun 17, 2026

Study contacts

Barry L Shulkin, MD
principal investigator · St. Jude Children's Research Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Methionine

Start the discussion